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Background Using data from a large European collaborative study, we aimed to
identify the circumstances in which treated HIV-infected individ-
uals will experience similar mortality rates to those of the general
population.
Methods Adults were eligible if they initiated combination anti-retroviral
treatment (cART) between 1998 and 2008 and had one prior CD4
measurement within 6 months. Standardized mortality ratios
(SMRs) and excess mortality rates compared with the general
population were estimated using Poisson regression. Periods of
follow-up were classified according to the current CD4 count.
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Results Of the 80 642 individuals, 70% were men, 16% were injecting drug
users (IDUs), the median age was 37 years, median CD4 count
225/mm3 at cART initiation and median follow-up was 3.5 years.
The overall mortality rate was 1.2/100 person-years (PY) (men: 1.3,
women: 0.9), 4.2 times as high as that in the general population
(SMR for men: 3.8, for women: 7.4). Among 35 316 individuals
with a CD4 count 5500/mm3, the mortality rate was 0.37/100 PY
(SMR 1.5); mortality rates were similar to those of the general
population in non-IDU men [SMR 0.9, 95% confidence interval
(95% CI) 0.7–1.3] and, after 3 years, in women (SMR 1.1, 95% CI
0.7–1.7). Mortality rates in IDUs remained elevated, though a trend
to decrease with longer durations with high CD4 count was seen.
A prior AIDS diagnosis was associated with higher mortality.
Conclusions Mortality patterns in most non-IDU HIV-infected individuals with
high CD4 counts on cART are similar to those in the general popu-
lation. The persistent role of a prior AIDS diagnosis underlines the
importance of early diagnosis of HIV infection.
Keywords HIV infection, CD4 lymphocyte count, mortality, anti-retroviral
therapy, highly active
Introduction
Immune restoration occurs in most HIV-infected pa-
tients treated with combination anti-retroviral therapy
(cART) and is associated with a dramatic decrease in
AIDS-related mortality.1–4 For the first time, it has
become conceivable that treated HIV-infected individ-
uals may experience mortality rates that are similar to
those seen in HIV-negative individuals of the same
age and gender.5,6 Indeed, among individuals in
high-income countries with a known date of HIV
seroconversion who were followed between 2004
and 2006, mortality in the first 5 years after serocon-
version was similar to that in the general population.4
The absolute number of circulating CD4þ cells/mm3
(the ‘CD4 count’) is the most commonly used marker
of HIV disease progression and of immune reconsti-
tution after cART, with a lower CD4 count predicting
the occurrence of both AIDS and non-AIDS-defining
diseases.7–9 A trend towards improved survival among
those with higher CD4 counts is apparent even among
untreated patients with a CD4 count4350/mm3.10,11
Currently, in most resource-rich countries, mortality
in HIV-infected individuals receiving cART remains
higher than in the general population12–16 even
among individuals who experience a good initial re-
sponse to cART.17 However, some subgroups do have
a more favourable prognosis, including men who have
sex with men (MSM) who initiated treatment for the
first time, whereas AIDS-free6 and individuals who
have maintained a high CD4 count while on cART
for 46 years.5 Beyond the immune restoration
measured in routine practice by the CD4 count, the
reconstitution of the T-cell subsets may, however,
remain incomplete despite several years of treat-
ment.18 In a large European collaboration of HIV co-
horts, we aimed to identify the optimal circumstances
in which treated HIV-infected individuals will experi-
ence similar mortality rates to those of the general
population. In particular, we wished to explore the
impact on the mortality rate of attaining and main-
taining over a long period, a CD4 count 5500/mm3 in
different subgroups.
Methods
Study population
The Collaboration of Observational HIV
Epidemiological Research in Europe (COHERE,
http://www.cohere.org) was established in 2005 with
the objective of conducting epidemiological research
on the prognosis of HIV-infected people across
Europe.19 The 33 participating observational cohorts
have been approved by local ethics committees or in-
stitutional review boards according to local regula-
tions. Each cohort submits information using a
standardized data format to one of two coordinating
centres at the Copenhagen HIV Project (CHIP),
Copenhagen, Denmark or the Institut de Sante´
Publique d’E´pide´miologie et de De´veloppement
(ISPED), University Bordeaux Segalen, France. Our
analyses were based on data merged in November
2008. Patients were eligible if they met the following
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criteria: at least 18 years of age at cART initiation,
cART initiation in 1998 onward, followed in an
European country, known date of birth and gender,
at least one CD4 measurement within 6 months prior
to cART initiation and at least 1 day of follow-up.
Statistical analysis
We used three complementary estimates to express
mortality.
(i) Mortality rates were expressed as number of
deaths per 100 person-years (PY) with 95%
confidence intervals (95% CIs) calculated
using the exact Poisson method. These reflect
mortality incidence over time.
(ii) Standardized mortality ratios (SMRs) were
used to compare, in a multiplicative way, the
mortality rates with those of the general popu-
lation. The SMR is the ratio of the number of
observed deaths to the number of expected
deaths. Expected deaths were obtained by
applying country-, calendar year-, gender- and
age-specific mortality rates for the general
population to the PY of follow-up of the HIV
cohort. Mortality rates for the general popula-
tion were extracted from the Human Mortality
Database, www.mortality.org, or from the
World Health Organisation statistical informa-
tion system (WHOSIS, http://apps.who.int/
whosis/data). SMRs were computed through
Poisson models offsetting expected mortality
rates, and adjusted for gender, age, HIV trans-
mission group and history of AIDS at cART ini-
tiation. A random-effect for cohort studies was
included to account for heterogeneity. An inter-
action term was included in the model to take
into account an effect modification between
HIV transmission category and age. SMRs
were then estimated for the whole study popu-
lation and separately by gender, age (18–39
years; 40–59 years; 560 years), HIV transmis-
sion group [injecting drug users (IDUs), MSM,
heterosexual], clinical AIDS at cART initiation
and the current CD4 count. To allocate PY and
events to the current CD4 count, each year of
age during follow-up was categorized according
to the lowest CD4 measurement during the cor-
responding year. Where the CD4 count was
missing for a particular age-year (1.3, 4.1 and
0.6% of overall PY, at the beginning, during and
end of follow-up, respectively), a last-observa-
tion-carried-forward method or other simple
methods were used to impute the missing
values (these methods were judged to provide
reliable estimates of SMRs in sensitivity ana-
lyses designed to assess the robustness of the
method, data not shown).
Our specific interest was in assessing mortal-
ity rates and SMRs during periods where the
CD4 count was 5500/mm3. Within this
subanalysis, we aimed to identify whether a
longer time spent with a CD4 count
5500/mm3 was associated with a higher likeli-
hood of similar mortality rates to those reported
in the general population. We thus estimated
SMRs accounting for all years of age with
CD4 counts 5500/mm3 with the following
time thresholds: 51 year spent with CD4
5500/mm3; 52 consecutive years spent with
CD4 5500/mm3, . . . , 55 consecutive years
spent with CD4 5500/mm3.
Mortality rates were considered as similar to
the general population when the 95% CI for the
SMR included the value 1 and when the point
estimate was close to 1, i.e. <1.2.
(iii) Excess mortality rates quantified, in an additive
way, the observed death beyond those expected.
These were estimated by subtracting the ex-
pected number of deaths from the observed
number, and dividing this by the total PY;
95% CIs were computed using the exact
Poisson method assuming that the reference
mortality rates were fixed.20 All statistical ana-
lyses were performed using Statistical Analysis
System software (SAS, 9.1).
Results
In the COHERE database, 80 642 patients from 23 co-
horts and 31 European countries were eligible for this
analysis out of a total of 94 295 HIV-infected adults
who initiated cART between 1998 and 2008 (Figure 1
and Supplementary Figure 1, available as
Supplementary Data at IJE online). Patients excluded
from the analysis (due to missing data on gender,
CD4 measures within 6 months prior cART initiation
or follow-up) did not differ from included patients in
terms of their gender, age, transmission category,
clinical stage, year of cART initiation or mortality
rate (data not shown). Overall, 70% of eligible partici-
pants were men and the median age at cART initi-
ation was 37 years (men 38 years, women 34 years)
(Table 1). IDU was the HIV transmission category in
16%, of whom 1% were 560 years of age. Among
men, 48% were MSM. Overall, 19% of individuals
had AIDS at cART initiation, the median CD4 count
was 225/mm3 (inter-quartile range: 107–357) and 44%
had a CD4 count <200/mm3 (men 45%, women 40%).
The median CD4 count at cART initiation was lower
in individuals aged 560 years as compared with
younger individuals. The median delay between HIV
diagnosis and cART initiation was shorter in older
individuals and was 0.3 and 1.2 years for patients
starting cART with CD4 cell count <200/mm3 and
5500/mm3, respectively. The median duration of
follow-up was 3.5 years. Of the total duration of
follow-up of 315 340 PY, 29% was spent with a CD4
count 5500/mm3.
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Mortality rates, SMRs and excess mortality
rates overall
Gender
Mortality rates were 1.15/100 PY overall, 1.29 in men
and 0.86 in women (Table 1). Overall, mortality was
higher than in the general population (SMR 4.2, 95%
CI 3.5–5.2), both in men (SMR 3.8, 95% CI 3.1–4.7)
and women (SMR 7.4, 95% CI 6.0–9.1). Conversely,
excess mortality rates were slightly lower in women
[0.74/100 PY (95% CI 0.60–0.92)] than in men [0.95/
100 PY (95% CI 0.78–1.16)].
Age
As expected, mortality rates increased with age,
whereas SMRs decreased with age from 8.5 at ages
<40 years to 1.7 at ages 560 years. Conversely, the
excess mortality rates increased with age from
0.73/100 PY at ages <40 years to 1.19/100 PY at
ages 560 years (Table 1). The excess mortality
represented 88, 75 and 41% of the observed mortality
among individuals <40 years, 40–59 years and 560
years, respectively. Thus, whereas older HIV-infected
individuals had mortality rates that were closer to
those of a general population of the same age and
gender when considered in relative terms, absolute
excess mortality was higher in older individuals and
this represented a smaller proportion of the observed
mortality rates (Table 1 and Figure 2).
Mortality rates, SMRs and excess mortality
rates with CD4 counts 5500/mm3
As the CD4 count increased, mortality rates dropped
and were closer to those of the general population.
Among 35 316 individuals with a CD4 count 5500/
mm3, the mortality rate was 0.37/100 PY (SMR 1.5,
95% CI 1.2–1.8) and excess mortality rate 0.12 (95%
CI 0.10–0.15) (Table 2). Overall, mortality rates
among the 24 479 HIV-infected men with a CD4
Figure 1 European country distribution of the study population within mortality analysis, the COHERE Collaboration
1998–2008
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count 5500/mm3 reached similar levels to those of
the general male population after 3 years in this
CD4 strata: SMR 1.0 (95% CI 0.8–1.4) (Figure 3a).
Among the 10 837 HIV-infected women with a CD4
count 5500/mm3, mortality rates did not reach simi-
lar levels to those of the general female population,
even after 5 years spent above this threshold
(Figure 3b). These results were similar in the sub-
group of individuals with a high CD4 count at cART
initiation.
Non-IDUs
Among non-IDUs, mortality rates were similar to
those of the general population in men with CD4
count 5500/mm3: SMR 0.9 (95% CI 0.7–1.2)
(Figure 3e and g). In women with a CD4 count
5500/mm3, mortality rates were similar to those of
the general population after 3 years in this CD4 strata,
SMR 1.1 (95% CI 0.7–1.7) (Figure 3f).
IDUs
Among 12 503 IDUs, mortality was 13.1 times (95% CI
10.5–16.5) higher than in the general population, 11.7
times (95% CI 9.4–14.7) higher in men and 22.7 times
(95% CI 18.0–28.7) higher in women; the excess mor-
tality rate was 2.29/100 PY (95% CI 1.83–2.87). Even
when the CD4 count was 5500/mm3, mortality rates
remained higher than those seen in the general popu-
lation, SMR 5.7 (95% CI 4.2–7.8), with an excess mor-
tality rate of 0.76 (95% CI 0.56–1.04). This was
apparent even after 5 years spent above this thresh-
old, though SMRs tended to decrease as individuals
attained a CD4 count 5500/mm3 for longer periods of
time (Figure 3c and d).
Figure 2 SMRs and mortality rates according to age in HIV-infected individuals after initiation of cART and in the general
population, the COHERE Collaboration 1998–2008 (logarithmic scale)
Table 2 SMR and excess mortality rates in HIV-infected individuals with a CD4 count 5500/mm3 after cART initiation,
according to gender and age
PY
Mortality rate/
100 PY (95% CI) SMR (95% CI)
Excess mortality rate/
100 PY (95% CI)
Global 91 891 0.37 (0.30–0.46) 1.5 (1.2–1.8) 0.12 (0.10–0.15)
Men (years) 65 697 0.43 (0.35–0.53) 1.4 (1.1–1.7) 0.12 (0.10-0.15)
18–39 32 565 0.31 (0.24–0.40) 2.5 (1.9–3.2) 0.18 (0.14-0.24)
40–59 30 216 0.48 (0.38–0.62) 1.3 (1.0–1.7) 0.12 (0.09–0.15)
560 2916 1.27 (0.88–1.82) 0.7 (0.5–1.0)
Women (years) 26 194 0.23 (0.17–0.32) 2.2 (1.6–3.0) 0.13 (0.09–0.17)
18–39 17 564 0.17 (0.12–0.24) 3.4 (2.5–4.8) 0.12 (0.09–0.17)
40–59 7938 0.32 (0.23–0.45) 1.9 (1.3–2.6) 0.15 (0.10–0.21)
560 692 0.77 (0.50–1.21) 1.0 (0.6–1.5) 0.03 (0.04 to 0.02)
cART: combination antiretroviral therapy; CI: confidence interval; HIV: human immuno-deficiency virus; PY: person-years.
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Age and baseline AIDS
The 1717 individuals aged 560 years who achieved a
CD4 count5500/mm3 experienced mortality rates that
were similar to the general population; this was true
for both genders (Table 2). Nevertheless, in the group
of older women who reached CD4 counts 5500/mm3,
the SMR was 1.7 (95% CI 0.7–4.0) among those who
had AIDS at cART initiation (Figure 4h).
Figure 3 SMRs according to gender, transmission group and time spent with CD4 count 5500/mm3 among HIV-infected
individuals with CD4 count 5500/mm3 after initiation of cART, the COHERE Collaboration 1998–2008. (a) men global; (b)
women global; (c) men IDU; (d) women IDU; (e) men heterosexual; (f) women heterosexual; (g) men who have sex with
men
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Among non-IDU men who had a CD4 count
5500/mm3, mortality rates were similar to those in
the general population at ages 540 years but were
higher at ages <40 years. Nevertheless, among men
aged 40–59 years who had high CD4 counts but who
had AIDS at cART initiation, the SMR was 1.3 (95%
CI 0.8–2.1) in heterosexuals and 1.2 (95% CI 0.8–2.0)
in MSM (Figure 4f and j).
Among non-IDU women aged <60 years who had a
CD4 count 5500/mm3, mortality rates were higher
than those of the general female population
(Figure 4h). However, after 1 year with a CD4 count
Figure 4 SMRs according to gender, age, transmission group and AIDS at baseline among HIV-infected individuals after
initiation of cART, overall and during periods with CD4 count 5500/mm3, the COHERE Collaboration 1998–2008. All CD4
cell counts: (a) men IDU; (c) women IDU; (e) men heterosexual; (g) women heterosexual; (i) men who have sex with men.
CD4 cell count 5500/mm3: (b) men IDU; (d) women IDU; (f) men heterosexual; (h) women heterosexual; (j) men who
have sex with men
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5500/mm3, 40- to 59-year-old non-IDU women
experienced similar mortality rates as those of the
general population, SMR 1.1 (95% CI 0.7–1.7); in con-
trast, women aged 18–39 years never experienced
similar mortality rates as those in the general
population.
Overall, AIDS at cART initiation was associated with
higher SMRs. This remained the case in all groups
even when the current CD4 count was 5500/mm3
(Figure 4).
Discussion
This large cohort collaboration includes more than
80 000 patients from 31 countries. Given this large
number of patients, as well as the inclusion of pa-
tients from 31 different European countries, and the
fact that many of the participating cohorts are based
within health-care delivery systems in these countries,
the results presented may be considered to provide a
fair representation of the wider situation of
HIV-infected individuals in Europe over the first
10 years of widespread cART use. Between 1998 and
2008, the mortality rate in cART-treated European
HIV-infected adults was 1.2/100 PY on average.
Although IDUs continued to experience greater mor-
tality than that seen in the general population, even
when they had attained a CD4 count 5500/mm3 for
more than 5 years, non-IDUs who attained a CD4
5500/mm3 experienced mortality rates that were
similar to those of the general population; this effect
was seen immediately after reaching the threshold in
men and after 3 years among women. AIDS at cART
initiation was, however, associated with higher SMRs,
regardless of the CD4 count attained.
The overall SMR among HIV-infected individuals on
cART in our study is close to recent reports 6,21 but
lower than those from previous studies,5,14 consistent
with a decrease in mortality reported in the most
recent years of the cART period.4
Gender
Higher SMRs in women compared with men have
already been reported.12,17,21 Non-IDU males aged
540 years with CD4 counts 5500/mm3 reached simi-
lar mortality rates as men in the general population.
Although the same was generally true of non-IDU
women, SMRs did remain high in some specific sub-
groups, e.g. those aged 18–39 years. This may reflect
differences between HIV-infected women and women
of the general population that may lead to a higher
mortality risk (e.g. lower socio-economic status22,23,
increased frequency of smoking24) which are not cap-
tured within the COHERE study. Of note, mortality
rates among women in the general population are
much lower than those among similarly aged men.
Conversely, the excess mortality rates were slightly
higher in men than in women, representing the
burden of mortality associated with HIV infection or
associated conditions from a public health stand
point.
Age
The higher SMRs seen in younger individuals are
partly explained by a higher proportion of IDUs in
this age group. After excluding IDUs, the age trend
remained, however, suggesting that other characteris-
tics (e.g. smoking or socio-economic level) may also
play a role. Older individuals had lower SMRs as com-
pared with younger ones, due to higher mortality
rates in the older general population, and higher
excess mortality rates, as previously described.15,17
From a public health perspective, these higher
excess mortality rates should lead to further explor-
ation of the causes of death in older HIV-infected in-
dividuals. In the French ‘Mortalite´ 2000-2005’
surveys, diversification of the causes of death was
particularly marked in older individuals, with higher
proportions of cancer- and cardiovascular-related
deaths.25
IDUs
Our results confirm that IDUs generally have a poor
prognosis, though those who experience a good im-
munological response to cART for sufficiently ex-
tended periods of time have the best prognosis.
Since adherence is a strong predictor of mortality,26
HIV-infected IDUs should therefore be reminded that
the ability to adhere to ART over the long term is
especially important for their health. In addition,
these results emphasize the importance of sustained
prevention of HIV infection in IDUs. In addition to
high-risk behaviours, the role of co-infection with
hepatitis C deserves further research.27
Baseline AIDS
Occurrence of AIDS before cART initiation resulted in
a poorer prognosis even in individuals who attained
CD4 counts 5500/mm3. Our findings provide further
arguments for early cART initiation in order to pre-
vent the occurrence of AIDS-defining events that may
still occur (albeit at low frequency) in high CD4
strata10 and which may have a long-term effect on
subsequent prognosis. In fact, the median CD4
count at starting cART was 225/mm3 (lower in older
individuals), highlighting the importance of wide-
spread HIV testing in order to increase earlier HIV
diagnosis.
Current CD4 count
We initially hypothesized that a longer time spent
with CD4 counts 5500/mm3 might permit treated
HIV-infected patients to attain mortality rates that
were similar to those of the general population.
When considering the overall sample of treated indi-
viduals, this was verified after 3 years in this CD4
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strata for men but not in women, even after 5 years
with a CD4 count 5500/mm3. Nevertheless, the effect
of time spent with a high CD4 count was weaker
when compared with the impact of other characteris-
tics such as IDU status or age. While some subgroups
(e.g. those aged 560 years or non-IDU men aged
540 years) experienced mortality rates that were
similar to the general population when their CD4
count was high, regardless of the time spent with a
high CD4, other subgroups did not (e.g. IDUs,
non-IDUs aged <40 years), even with a high CD4
nadir. This is in accordance with other studies
which have reported that CD4 measurement most
strongly predictive of death, non-AIDS-related mor-
tality28 or AIDS and non-AIDS-defining cancers29
was the most recent one. Of note, the effect of time
spent with a high CD4 count was apparent in female
non-IDUs aged 40–59 years, who experienced similar
mortality rates as the general population after 1 year
with a CD4 count 5500/mm3.
In the subgroups where we see a higher risk of
death despite a CD4 count 5500/mm3, we suggest
that any excess mortality may be driven by behaviour-
al or socio-economic characteristics. If this is the case,
then a treatment target of a CD4 count 5500/mm3
may not necessarily improve the prognosis of this
group, as suggested by a recent pooled analysis
among non-treated individuals in high-income set-
tings.11 When compared with our study of treated
individuals, these authors report a similar SMR
among MSM with a CD4 count 5500/mm3 and a
higher SMR among heterosexuals.11
Strengths and generalizability
Only one previous study has analysed SMRs according
to updated CD4 in treated individuals from two
French cohorts.5 The current study provides further
evidence on this topic with greater potential for ex-
trapolation across Europe.
For the purpose of this analysis, which was to iden-
tify conditions associated with low mortality rates, we
selectively identified patients who succeeded in at-
taining a high CD4 count on cART. Our selection
means that these individuals had to survive long
enough for the count to reach this high level. Other
studies with similar aims to our own selected individ-
uals treated with cART for at least 24 weeks.17
Identification of the optimal conditions was useful
in order to define a target for complete success of
treatment in some subgroups and to advance research
as to how these favourable outcomes may be achieved
in other subgroups (e.g. younger individuals, women,
IDUs). Despite the selection of individuals with a
good response to treatment, however, the mortality
among some subgroups remained substantially
higher than in the general population of the same
age and gender.
Our results apply to the follow-up of HIV-infected
individuals over the first 10 years of cART. Further
studies will be necessary to analyse mortality rates
across several decades of cART. Early aging, which
involves immune, cerebral, cardiovascular, bone and
metabolic systems, may lead to earlier mortality in
this population over the long term.30
In order to compare mortality rates we used two
estimators. The main analysis was based on SMRs
that identified conditions that allow HIV-infected
adults to reach mortality rates similar to those of
the general population and provided a multiplicative
figure which may be interpreted as a relative risk.
When mortality was higher than in the general popu-
lation and when the reference mortality rates in the
general population differed according to subgroups, in
particular for gender and age, excess mortality rates
were also used in order to interpret the results in
terms of public health burden.
Limitations
A description of the causes of death would help to
determine if the excess mortality in some subgroups
of HIV-infected individuals was related to AIDS con-
ditions, to comorbidities such as hepatitis C or B or to
emerging morbidities such as cardiovascular disease
or cancer. Nevertheless, such a description requires
standardized collection and determination of the
underlying cause of death.25,31 Such a valid determin-
ation of the causes of death was not available in our
study, though investigators of HIV cohorts should
make every possible effort to incorporate standardized
collection and validation of data on causes of death.
Increasing use of the Coding Causes of Death in HIV
(CoDe) protocol for describing the causes of death
among those with HIV is likely to result in improve-
ments in cause of death records in the future.31
We acknowledge that our results do not directly
apply to HIV-infected individuals living in low-
resource settings, due to differences in HIV care man-
agement, socio-economic conditions, characteristics of
patients and the spectrum of morbidities, with active
tuberculosis and invasive bacterial diseases being
more frequent in these settings than in high-income
countries.32
We chose to refer to all-cause mortality rates in the
general population, which include HIV-related deaths.
However, HIV-related mortality represents only a
small proportion of all-cause mortality in the general
population in Europe, allowing us to consider the
general population mortality rates as a reasonable
proxy for the mortality rates in a non-HIV-infected
population.
Although data available from the general population
did not allow us to take into account other risk for
mortality such as smoking, socio-economic level or
IDU, we considered the mortality rates in the general
population of the same age and gender as low mor-
tality rates that could be a rational target for therapy
to achieve for all subgroups of patients.
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Clinical relevance
In conclusion, among treated HIV-infected individuals
who attained a CD4 count 5500/mm3, mortality rates
were similar to those of the general population
in non-IDU men and after 3 years in this CD4
strata in non-IDU women. Among IDUs, mortality
rates remained higher than those in the general popu-
lation, even after 5 years spent with a CD4 count
5500/mm3, though SMRs tended to decrease with
longer durations above this threshold. Further studies
will be necessary to confirm this trend across several
decades of cART. The persistent influence of a prior
AIDS diagnosis even among those attaining a high
CD4 count, underlines the importance of the current
public health calls for earlier identification of HIV in-
fection and entry into care. Our results emphasize the
fact that factors other than quantitative immune res-
toration are necessary in order to reach low mortality
rates in HIV-infected individuals.
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Supplementary Data are available at IJE online.
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KEY MESSAGES
 The mortality rate in HIV-infected adults after cART initiation in Europe between 1998 and 2008 was
1.2/100 PY on average, consistent with a decrease in mortality reported in the most recent years of
the cART period.
 In a large European collaborative study, non-IDUs infected by HIV and treated by cART who attained
a CD4 count 5500/mm3 experienced mortality rates that were similar to those of the general popu-
lation, immediately after reaching the threshold in men and after 3 years among women.
 Mortality rates in treated IDUs remained elevated, though they tend to decrease with longer dur-
ations with high CD4 count. AIDS at cART initiation was associated with higher SMRs, regardless of
the CD4 count attained.
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Since 1996, widespread availability of combination
antiretroviral therapy (ART) has significantly im-
proved survival of HIV-infected persons in industria-
lized countries.1,2This has prompted researchers in
Europe2,3and North America1,2,4to investigate whether
mortality among HIV-infected persons receiving ART
might reach levels similar to those in the general
population.
In this paper by Lewden et al.,5 more than 80 000
patients from 31 European countries are included in
an analysis to estimate crude ART patient mortality
rates for persons 518 years of age, who initiated ART
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